Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IKZF1, also known as Ikaros, is a zinc finger transcription factor crucial for lymphoid cell development and hematopoiesis. It regulates gene expression through chromatin remodeling and interacts with co-repressors and co-activators. IKZF1 is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia (B-ALL), leading to poor prognosis. While direct targeting of IKZF1 is not currently possible, downstream pathways affected by its loss are being explored for therapeutic intervention.
Indirectly targetable via downstream pathways like JAK/STAT signaling or PI3K pathway. Casein kinase 2 inhibitors can restore some IKZF1 function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IKAROS family zinc finger 1.